Orbcel

Orbsen Therapeutics is a clinical-stage biotechnology company specializing in the development of high-purity stromal cell therapies for inflammatory and immune-mediated diseases. The company's core technology is the ORBCEL platform, which utilizes the CD362 (Syndecan-2) cell surface marker to isolate a specific, potent population of mesenchymal stromal cells (MSCs) from various human tissues. Unlike traditional MSC therapies that use heterogeneous cell mixtures, Orbsen's purified ORBCEL cells aim to provide enhanced therapeutic consistency and efficacy. The company is currently advancing a diverse pipeline, with lead programs in Phase 2 clinical trials for indications such as diabetic kidney disease, acute respiratory distress syndrome (ARDS), and primary sclerosing cholangitis. Headquartered in Galway, Ireland, Orbsen leverages extensive academic and clinical partnerships to drive its regenerative medicine portfolio.